Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807276 | 1.00 | GLP1R (0.62) | GLP1RNOD1FOLH1HPGDHTT | |
| SCHEMBL14238765 | 1.00 | GLP1R (0.62) | GLP1RNOD1FOLH1HPGDHTT | |
| SCHEMBL14819793 | 1.00 | GLP1R (0.62) | GLP1RNOD1FOLH1HPGDHTT | |
| SCHEMBL15357515 | 1.00 | GLP1R (0.62) | GLP1RNOD1FOLH1HPGDHTT | |
| SCHEMBL10046211 | 1.00 | GLP1R (0.62) | GLP1RNOD1FOLH1HPGDHTT | |
| SCHEMBL14998225 | 1.00 | GLP1R (0.62) | GLP1RNOD1FOLH1HPGDHTT | |
| SCHEMBL13165198 | 1.00 | GLP1R (0.62) | GLP1RNOD1FOLH1HPGDHTT | |
| SCHEMBL71264 | 1.00 | GLP1R (0.62) | GLP1RNOD1FOLH1HPGDHTT | |
| SCHEMBL71129 | 1.00 | GLP1R (0.62) | GLP1RNOD1FOLH1HPGDHTT | |
| SCHEMBL22402582 | 0.96 | GLP1R (0.67) | GLP1RNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737612-B2 | Antagonistic DR3 ligands | NOVO NORDISK A/S (DK) | 2017-08-22 | — | — | US | disclosed |
| US-9713644-B2 | Antagonistic DR3 ligands | NOVO NORDISK A/S (DK) | 2017-07-25 | — | — | US | disclosed |
| US-20170190757-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2017-07-06 | — | — | US | disclosed |
| US-9486505-B2 | Glucagon analogues | NOVO NORDISK A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-9480753-B2 | FGF21 derivatives with albumin binder A-B-C-D-E- and their use | NOVO NORDISK A/S (DK) | 2016-11-01 | — | — | US | disclosed |
| US-9480753-B2 | FGF21 derivatives with albumin binder A-B-C-D-E- and their use | NOVO NORDISK A/S (DK) | 2016-11-01 | — | — | US | disclosed |
| US-20160271263-A1 | Acylated Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-09-22 | — | — | US | disclosed |
| US-9365632-B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | SANOFI (FR) | 2016-06-14 | — | — | US | disclosed |
| US-20160002311-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-01-07 | — | — | US | disclosed |
| US-9181305-B2 | Exendin-4 peptide analogues | SANOFI (FR) | 2015-11-10 | — | — | US | disclosed |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-07 | — | — | US | disclosed |
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2011-04-07 | — | — | US | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | NOVO NORDISK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | NOVO NORDISK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190757-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 1856/4885FOLH1 303/4885 |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | FABP1, FABP4, FGFR1 | GLP1R 45/4885NOD1 1001/4885FOLH1 1037/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1340/4885FOLH1 450/4885 |
| US-20160002311-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 1856/4885FOLH1 303/4885 |
| US-20100305032-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 575/4885FOLH1 555/4885 |
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 1856/4885FOLH1 303/4885 |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 323/4885FOLH1 411/4885 |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | GLP1R, IAPP, SLC5A1 | GLP1R 1/4885NOD1 221/4885FOLH1 1590/4885 |
| US-20160271263-A1 | Acylated Glucagon Analogues | GLP1R, GCG, IAPP | GLP1R 1/4885NOD1 2294/4885FOLH1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.